Transient leukemia (TL) has been observed in approximately 10% of newborn infants with Down syndrome (DS). Although treatment with cytarabine is effective in high-risk TL cases, approximately 20% of severe patients still suffer early death. In this study, we demonstrate abundant KIT expression in all 13 patients with GATA1 mutations, although no significant difference in expression levels was observed between TL and acute myeloid leukemia. Stem cell factor (SCF) stimulated the proliferation of the TL cells from five patients and treatment with the tyrosine kinase inhibitor imatinib suppressed the proliferation effectively in vitro. To investigate the signal cascade, we established the first SCF-dependent, DS-related acute megakaryoblastic leukemia cell line, KPAM1. Withdrawal of SCF or treatment with imatinib induced apoptosis of KPAM1 cells. SCF activated the RAS/MAPK and PI3K/AKT pathways, followed by downregulation of the pro-apoptotic factor BIM and upregulation of the anti-apoptotic factor MCL1. Although we found novel missense mutations of KIT in 2 of 14 TL patients, neither mutation led to KIT activation and neither reduced the cytotoxic effects of imatinib. These results suggest the essential role of SCF/KIT signaling in the proliferation of DSrelated leukemia and the possibility of therapeutic benefits of imatinib for TL patients.
Introduction
Children with Down syndrome (DS) are predisposed to developing leukemia. A leukemoid reaction occurring uniquely in approximately 10% of newborn infants with DS referred to as transient myeloproliferative disorder or transient leukemia (TL). This disorder, in most cases, resolves spontaneously within 3 months after birth. Of all TL patients, approximately 20-30% develop myeloid leukemia of Down syndrome (ML-DS) within 4 years. 1 In comparison with non-DS children with acute myeloid leukemia (AML), ML-DS patients have a better clinical outcome. 2, 3 However, approximately 20% of the patients with severe TL are still subject to life threatening or fatal complications. 4, 5 Improved treatments for TL are necessary for a better long-term prognosis of DS patients.
Almost all patients with TL and ML-DS have a somatic mutation in GATA1 in their blast cells. GATA1 transcription factor is required for the differentiation of erythroid and megakaryocytic cells. Most of the mutations occur in the first coding exon and result in expression of a truncated GATA1 protein (GATA1s). 6 Bourquin et al. 7 showed that the gene expression profile in ML-DS is distinctly different from both non-DS-acute megakaryocytic leukemia (AMKL) and AML. Focusing on the gene expression alterations attributed to GATA1s they suggested that in ML-DS, several pro-proliferative genes repressed by GATA1 were aberrantly regulated and one of those was KIT. These results indicated the possibility that the loss of repression of the genes by GATA1s contributes to the pathogenesis of ML-DS.
The proto-oncogene KIT encodes a transmembrane type III tyrosine kinase, which is the receptor for stem cell factor (SCF). KIT is expressed in approximately 70% of de novo AMLs and 95% of relapsed AMLs. 8 Recent reports showed that KIT is also expressed in almost all TL patients. 5, 9 However, little is known about the expression level of KIT and the functional roles of SCF/KIT pathway in TL.
In the present study, we show that SCF/KIT signaling has an essential role in the proliferation and survival of blast cells from DS-related leukemia and the possibility of therapeutic benefits of imatinib for severe TL patients.
Materials and methods

Patient samples and cell culture
All clinical samples were obtained with informed consent, and this study was approved by the Ethics Committee of Hirosaki University. Mononuclear cell fractions were obtained by Ficoll-Hypaque separation from peripheral blood of TL patients and bone marrows of acute leukemia patients. Fractionated cells of case TL1, 7, 9, 14 and 15 were resuspended in cell preservation medium CP-1 (Kyokuto Pharmaceutical Industrial Co., Tokyo, Japan) and kept in a À80 1C freezer until use. These cells were thawed and incubated in Iscove's Modified Dulbecco's medium (Invitrogen, Carlsbad, CA, USA) containing 10% fetal bovine serum overnight at 37 1C in 5% CO 2 . After the incubation, cells were used for assays.
Recombinant human SCF, erythropoietin, thrombopoietin, granulocyte-colony stimulating factor, interluekin-3 (IL-3) and murine IL-3 were kindly provided by Kirin Brewery (Tokyo, Japan). Imatinib was kindly provided from Novartis Pharmaceuticals (Basel, Switzerland). U0126, SU6656 and LY294002 were purchased from Calbiochem (San Diego, CA, USA).
K562, HEL and CMK11-5 cell lines were established from patients diagnosed with chronic myelogenous leukemia, erythroleukemia and ML-DS, respectively. KPAM1 cells, derived from ML-DS, were cultured in RPMI1640 supplemented with 10% fetal bovine serum and 50 ng/ml SCF. The murine pro-B cell line Ba/F3 was maintained in RPMI1640 supplemented with 10% fetal bovine serum and 1 ng/ml IL-3.
Case
The KPAM1 cell line was derived from a 3-year-old girl with ML-DS. She was diagnosed with TL at the age of 2 months. Her disease evolved to refractory anemia with excess blasts (RAEB) with monosomy 7 at 1 year of age, then AMKL at 2 years. Her disease was in remission during treatment but relapsed, at which point she received a peripheral blood stem cell transplant from her mother at 2 years and 8 months. Engraftment was prompt, but her disease relapsed soon and she died 165 days after peripheral blood stem cell transplant.
Quantitative real-time polymerase chain reaction analysis RNA was reverse transcribed with the iScript cDNA synthesis kit (Bio-Rad Laboratories., Hercules, CA, USA). Quantitative realtime polymerase chain reaction (qRT-PCR) was performed with iQ SYBR green supermix kit and the Chromo4 Real-time PCR system (Bio-Rad Laboratories). Primers for qRT-PCR analysis were designed by the Perfect Real Time Support System for Array (Takara Bio., Otsu, Shiga, Japan).
Retroviral vectors and transduction
The full length of KIT cDNA was inserted into the retroviral vector pMX-ires-CD8 (kindly provided by Dr Mano, Jichi Medical University). Mutant KIT expression vectors were generated by PCR-mediated mutagenesis. Retroviral infection method was described earlier. 10 Cell proliferation assay 
Detection of KIT mutations
RNA was reverse transcribed and the entire coding regions of KIT were amplified. Direct sequencing analysis was performed. The primers used for KIT mutation analysis are shown in the Supplementary data (Supplementary Table S1 ).
Results
Abundant expression of KIT in TL blast cells
We analyzed KIT expression in TL blast cells to compare the expression with other pediatric leukemic cells by qRT-PCR. Analyzed samples included 5 acute lymphoid leukemias, 19 AML (5 M1, 7 M2, 4 M4 and 3 M7 patients), 13 TL, 4 ML-DS cases and 3 ML-DS cell lines. The relative expression levels normalized to GAPDH expression, arbitrarily set at 1000 in TL were distributed from 4.04 to 25.03, averaging 13.42 (Table 1 and Figure 1 ). ML-DS patient samples expressed KIT at lower levels than did TL samples (the average was 8.07, Figure 1a) . Although a significant difference in expression levels was not observed between TL and AML, the data demonstrated that KIT was uniformly expressed in TL cells at a relatively high level. To investigate the possibility of autocrine mechanisms, we also examined SCF expression. qRT-PCR analysis showed that SCF mRNA was expressed at extremely low levels in TL cells and there were no significant differences in SCF expression among AML, TL and ML-DS (Figure 1b) .
Proliferation of TL blast cells is stimulated by SCF and abrogated by imatinib
To investigate the function of KIT in TL cells, we cultivated TL cells with various growth factors including SCF, erythropoietin, thrombopoietin, granulocyte-colony stimulating factor and IL-3. Although TL blast cells did not grow without exogenous cytokines in vitro (data not shown), TL cells from all five patients examined proliferated in response to SCF in a dosedependent manner. Maximal response was observed at the highest concentration examined (200 ng/ml) of SCF ( Figure 2a ). Three of five TL samples also responded to thrombopoietin but the extent of growth was less than that observed with SCF. These results suggested that SCF/KIT signaling plays key role in the proliferation of TL blast cells.
To confirm the involvement of SCF/KIT signaling in proliferation of TL blast cells, we determined whether a KIT inhibitor, imatinib, would affect growth. Treatment of TL cells with imatinib resulted in a significant decrease in cell proliferation in a dose-dependent manner ( Figure 2b ). By contrast, imatinib treatment of CMK11-5 cells, which possess an active JAK3 mutation, had no effect on proliferation. 11 It was reported that the overexpression of the wild-type FLT3 induced the ligand-independent phosphorylation in infantile acute lymphoid leukemias blasts cells. 12 Therefore, it is very interesting to know if the overexpression of KIT in TL cells results in constitutive autophosphorylation. To study this, KIT phosphorylation was assessed in frozen stocked cells. Western blotting analysis showed that various levels of KIT phosphorylation in all five TL samples examined ( Figure 2c ). We next examined the KIT activation in TL blast cells after culturing without exogenous SCF. Surprisingly, KIT phosphorylation was induced after overnight culture and remained at the same levels up to 12 h (Figure 2d ). To examine the inhibitory effects of imatinib on KIT activation, blast cells were treated with the inhibitor, with or without exogenous SCF. Higher levels of KIT phoshorylation were detected in SCF-stimulated cells compared with unstimulated cells. A total of 1mM of imatinib inhibited KIT phosphorylation although faint signals remained (Figure 2e ). These results suggest that the abundant KIT expression in TL blasts might induce the autophosphorylation, although the level of KIT phosphorylation without exogenous SCF is insufficient for proliferation of TL blast cells in vitro.
Establishment of a novel SCF-dependent cell line from a female ML-DS patient
Although our study suggested the involvement of SCF/KIT signaling in TL cell proliferation, it was difficult to study the mechanism of signal transduction in TL cells because of the limited numbers of cells and the absence of appropriate cell models. Therefore, we established a growth factor-dependent cell line KPAM1 from ML-DS blast cells. Table S2 ). GATA1 mutation analysis revealed a deletion of two nucleotides in the first coding exon, which caused a premature stop codon by frame-shifting, and resulted in the expression of GATA1s in this cell line (Supplementary Figure S1b and c) .
SCF stimulation of KPAM1 cells activated AKT and ERK
To investigate the growth factor responsiveness of KPAM1, the cells were cultured with erythropoietin, thrombopoietin, granulocyte-colony stimulating factor or IL-3 instead of SCF. KPAM1 cells did not respond to any growth factors examined (Figure 3a) . In this respect, KPAM1 resembled TL blasts (Figure 2a) . We then investigated downstream pathways implicated in KIT-mediated signal transduction in KPAM1 cells. For this purpose, SCF-stimulated cells were analyzed for phosphorylation of KIT, AKT, ERK1/2 and SRC by western blotting analysis. Phosphorylations of both AKT and ERK were detected simultaneously with KIT activation, whereas the SRC family proteins were not phosphorylated (Figure 3b ). Furthermore, addition of imatinib inhibited the phosphorylations of KIT, AKT and ERK in a dose-dependent manner (Figure 3c ).
We asked whether these signal pathways were involved in proliferation of KPAM1 cells. For this purpose, various signal transduction inhibitors were added to the culture medium, and cell growth was assessed. Proliferation of KPAM1 cells was significantly reduced by imatinib, PI3K inhibitor LY294002 and MEK inhibitor U0126. However, KPAM1 cells were less sensitive to SRC inhibitor SU6656 than CMK11-5 and K562 cells (Figure 3d ). These results suggest the critical roles of PI3K/ AKT and RAS/MAPK pathways in the proliferation of KPAM1 cells.
Withdrawal of SCF from KPAM1 cells induces apoptosis
To further investigate the functional role of the SCF/KIT pathway in DS-related leukemia, we studied the consequences of removing SCF from KPAM1's culture medium. Withdrawal of SCF induced cell death accompanied by morphological changes. The fragmentation of nuclei and formation of apoptotic bodies were observed (Figure 4a ). Furthermore, we detected KIT mRNA was quantified by qRT-PCR and expressed as the relative mRNA level normalized to GAPDH expression arbitrarily set at 1000.
Role of SCF/KIT signaling in TL of Down syndrome T Toki et al cleavage of PARP, an important marker of caspase 3-mediated apoptosis (Figure 4b ). These results suggested that SCF deprivation induced apoptosis in KPAM1 cells. The relative levels and interactions of anti-apoptotic and pro-apoptotic BCL2 family proteins determine whether a cell survives or undergoes apoptosis. 13 Therefore, we analyzed the expression levels of BCL2 family members, including three antiapoptotic proteins (BCLX, MCL1 and BCL2) (data not shown), and eight pro-apoptotic members, which included, BIM, BID, BAD, BAX, BOK, BIK, BMF and PUMA (data of latter five not shown). Among the examined proteins, only MCL1 and BIM changed significantly in expression. MCL1 was slightly decreased after 8 h starvation, while BIM was upregulated within 4 h starvation (Figure 4b) .
To further understand the effects of SCF/KIT signaling on the expression of BIM and MCL1, we performed western blotting analysis. As shown in Figure 4c , a band shift of BIM was observed immediately and transiently after SCF stimulation. The shifted bands are reportedly due to phosphorylation of BIM, and the phosphorylation promotes proteasome-dependent degradation. 14 The results showed that imatinib and U0126 efficiently reduced the shift (Figure 4d ). These results suggested that the RAS/MAPK pathway participated in the regulation of BIM protein downstream of SCF/KIT signaling in this cell line. With regard to MCL1, upregulation was observed after 2 h SCF stimulation (Figure 4c ). The upregulation of MCL1 was effectively inhibited by treatment with imatinib, U0126 or LY294002 (Figure 4e) , suggesting that the expression of MCL1 is regulated by not only the RAS/MAPK pathway but also the PI3K/AKT pathway. These results suggest that the inhibition of SCF/KIT signaling induces apoptosis in this cell line accompanied by up-and downregulation of BIM and MCL1, respectively.
KIT gain-of-function mutations were not present in TL cases
Mutations in KIT are important for tumor growth and progression in a variety of neoplasms, including mast cell diseases, gastrointestinal stromal tumor and AML. A previous report showed that no mutations were detected in 14 ML-DS and 4 TL patients. 15 However, the screening of KIT mutation was restricted to one of the hot spots, exon 17. To examine whether mutations in KIT are involved in the etiology or aberrant proliferation of TL blast cells, we screened the entire coding region of KIT in 14 TL patients. In our screening, two had novel substitutions: patient TL9 had a S854P change and the other patient, TL3, had a D910Y change. Both substitutions were located in the distal kinase domain of KIT protein (Figure 5a ). To determine whether these substitutions were polymorphisms or mutations, we performed direct sequence analysis of exons 18 and 20 of the KIT gene using genomic DNA from 50 unrelated controls. Identical substitutions were not detected (data not shown).
To investigate whether or not these mutations involved gainof-function, we first generated murine IL-3-dependent cell line Ba/F3 expressing either KIT S854P or KIT D910Y As shown in Figure 5b , expression of either KIT mutation did not confer factor-independent cell growth to Ba/F3 cells. Although Ba/F3 cells expressing KIT D910Y proliferated in response to SCF in a dose-dependent manner, KIT S854P cells did not grow. This result suggested that KIT S854P was a loss-of-function mutation. Next, we transduced the mutant KIT expression vectors to KPAM1 cells. As positive controls, we used KIT D816V active mutant. As shown in Figure 5c , neither exogenous expression of wild-type KIT, KIT S854P nor KIT D910Y conferred SCF-independent growth to KPAM1 cells, except for the KIT D816V mutation. The growth of KPAM1 cells expressing loss-of-function mutation KIT S854P was slightly repressed in comparison with other transduced cells at more than 50 ng/ml of SCF stimulation. However, the conversion of optical densities into cell densities according to the standard curves indicated that the dominant negative effect of KIT S854P was extremely weak or absent (Supplementary Figure S2) .
A number of imatinib-resistant KIT mutations including KIT D816V have been reported. 16 To examine whether the mutant KIT proteins found in TL patients affected growth inhibition by imatinib, cell proliferation assay was performed with various concentrations of imatinib. As shown in Figure 5d , all assessed cell lines except the cell line expressing KIT D816V were significantly reduced in growth by imatinib in a dose-dependent manner. These results suggested that the KIT mutations identified in TL did not induce imatinib resistance.
Discussion
In this paper, we showed that SCF alone could support the growth of TL blast cells. Abnormalities in KIT expression and function are assumed to play important roles in the pathogenesis of several human cancers. Two principal mechanisms of KIT dysregulation in human malignancies have been described. One Role of SCF/KIT signaling in TL of Down syndrome T Toki et al mechanism is gain-of-function mutation of KIT and the other is autocrine or paracrine production of SCF. We found 2 novel KIT missense mutations out of 14 TL patients. However, neither mutation was an activating mutation, suggesting that these mutations were 'passengers' and did not contribute to leukemogenesis in DS. It has been proposed that TL originates from Role of SCF/KIT signaling in TL of Down syndrome T Toki et al the fetal liver. 17 Interestingly, high levels of SCF expression have been observed in human fetal liver within a restricted time period. 18 Furthermore, a recent report showed the transient hyperproliferation of fetal hepatic megakaryocytic progenitors in GATA1s knock-in mouse. 19 Our present data, together with these findings, suggest that paracrine activation of the SCF/KIT pathway might play very important roles in the expansion of TL cells in the fetal liver.
We showed that KIT was uniformly expressed in TL cells at a relatively high level, although KIT expression in TL was not higher than in AML in general. Recently, Kindler et al. 20 reported that imatinib is effective only in small subgroup of AML patients without activating KIT mutations. It is conceivable that the therapeutic potential of KIT inhibitor is primarily determined by dependency of the survival or growth of leukemic cells to SCF/KIT signaling. The proliferative response of primary AML cells to SCF is very heterogenous and is not correlated with the number of KIT. 21 In contrast to AML, all TL cells examined proliferated well in response to SCF (Figure 2a) . Therefore, KIT will be a good candidate as a therapeutic target in TL. Figure 4d , cell lysate was prepared. Western blotting was performed for MCL1. IM, imatinib; U, U0126; LY, LY294002; SU, SU6656; or MG, MG132; SCF, stem cell factor.
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Following stimulation of KIT with SCF, multiple downstream signal transduction components are activated. However, the pivotal downstream cascades were unclear in both TL and ML-DS blast cells. In this report, we established the first SCFdependent ML-DS cell line, and demonstrated that PI3K/AKT and RAS/MAPK signaling pathways had essential roles in proliferation of the cell line. This novel cell line may be a useful model for the identification of therapeutic molecules against TL and/or ML-DS.
Apoptosis-related molecules are common targets in therapeutic approaches to neoplasms. We showed that BCL2 family members, BIM and MCL1, are involved in apoptosis and survival of KPAM1 cells. Our results suggest that SCF/KIT signaling promotes the survival of KAPM1 cells by (1) protecting them from BIM-mediated apoptosis and (2) inducing antiapoptotic effects mediated by MCL1. Identification of the molecules inducing upregulation of BIM or downregulation of MCL1 might prove useful in the identification of novel molecular targets for treating TL or ML-DS.
Imatinib inhibits tyrosine kinase platelet-derived growth factor receptor (PDGF-R) and ABL, as well as KIT. TL is sometimes associated with liver fibrosis, which is life threatening and often fatal. 4, 5 Transforming growth factor-b1 and PDGF were reported to be key mediators in fibrogenesis. 22 Recently, we and others reported that PDGF and transforming growth factor-b1 were abundantly expressed in TL blasts. 23, 24 ABL has been shown to be a downstream target of the activated transforming growth factor-b receptor. The inhibition of ABL activity with imatinib ameliorated renal fibrosis in an experimental model. 25 PDGF is the most potent proliferating stimulus for hepatic stellate cells. Inhibition of the function of PDGF/PDGF-R attenuated the development of experimental liver fibrosis. 26 Yoshiji et al.
27
demonstrated the usefulness of imatinib in suppression of liver fibrosis development. It might be expected that the treatment of TL cases with imatinib would result in inhibition of TL blast growth and also improvements in liver fibrosis. Recently, Klusmann et al. 5 showed that low-dose cytarabine treatment had a beneficial effect on high-risk TL cases. However, the treatment was insufficient to prevent the progression from TL to ML-DS. DS children suffer high rates of treatment toxicity, with an increased risk of treatment-related death. 2, 3 Combining cytarabine and KIT-targeting tyrosine kinase inhibitor treatments might exterminate the TL clone without serious drug-related toxicity and provide a beneficial therapeutic effect in cases of severe TL.
Conclusion
SCF/KIT signaling stimulated TL blast proliferation. The treatment of TL blasts with imatinib suppressed the proliferation effectively in vitro. We established the first SCF-dependent ML-DS cell line, KPAM1, and elucidated signal cascades downstream from SCF/KIT signaling which promoted survival of this cell line. These results suggest the essential role of SCF/KIT signaling in DS-related leukemia, and the possibility of therapeutic benefits from KIT-targeting tyrosine kinase inhibitor treatment of severe TL patients. 
